Our findings suggest that targeting this JNK – “ROS defense” axis in combination with current chemotherapeutic regimens may be a rational approach to overcome the therapy resistance of pancreatic cancer. The gene discussed is MAPK8; the disease is familial pancreatic carcinoma.